CVS Settles $36.5M Over Fraudulent Insulin Claims

• •CVS settled for $36.5 million over fraudulent insulin billing practices.
• •Minnesota's share includes over $400,000 in restitution to its Medicaid program.
• •The settlement involves allegations of false claims submitted from 2010 to 2020.

CVS Pharmacy has reached a $36.5 million settlement for allegedly overbilling government healthcare programs for insulin pens. Minnesota will receive over $850,000 from this settlement, including more than $400,000 in direct restitution to its Medicaid program. The allegations state that CVS submitted false claims for insulin pens from 2010 to 2020, including dispensing more insulin than prescribed and requesting reimbursement for ineligible refills. Minnesota Attorney General Keith Ellison emphasized the importance of accountability for corporations that defraud Medicaid. The settlement was part of a broader multistate effort involving 37 attorneys general and the federal government. The investigation was conducted by the National Association of Medicaid Fraud Control Units and the U.S. Attorney’s Office for the Southern District of New York. While the settlement resolves the allegations, it remains unclear if CVS will face additional penalties or changes in practices beyond this agreement.